David Arkowitz
CIK 1296999 · Chief Financial Officer · last filed 2025-11-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.51M
Companies
10
Total Filings
72
Lifetime Open-Market Net
$88.4K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IBIO | Director | 18,382 | $1.39 | $25.6K | $50.0K | 3 | 2025-11-24 |
| KINETA, INC./DE (KA) Delisted | Director | — | $0.57 | — | $0 | 2 | 2024-09-05 |
| MCRB | Chief Financial Officer | 9,122 | $4.80 | $43.8K | -$9.7K | 8 | 2024-02-16 |
| F-star Therapeutics, Inc. (FSTX) Delisted | Director | 0 | $7.12 | $0 | $0 | 3 | 2023-03-09 |
| KINETA, INC./DE (YMTX) Delisted | Director | 621 | $13.23 | $8.2K | $0 | 2 | 2021-06-04 |
| FLXN | Chief Financial Officer | 220,719 | $24.65 | $5.44M | $102.9K | 17 | 2021-05-12 |
| F-star Therapeutics, Inc. (SBPH) Delisted | Director | 9,482 | — | — | $30.6K | 12 | 2020-11-23 |
| KINETA, INC./DE (PTI) Delisted | Director | — | — | — | $0 | 2 | 2020-07-01 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | EVP, CFO and CBO | 1,806 | — | — | -$85.4K | 20 | 2011-06-01 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Chief Financial Officer | — | — | — | $0 | 1 | 2007-03-14 |
Recent Filings · Page 3 of 8
72 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-03-03 | FLXN | Grant (A) | +71,900 | $0 | EDGAR |
| 2021-01-07 | FLXN | Sell (S) | −6,073 | -$67.6K | EDGAR |
| 2020-12-28 | KINETA, INC./DE (YMTX) Delisted | Grant (A) | +4,347 | $100.0K | EDGAR |
| 2020-11-23 | F-star Therapeutics, Inc. (SBPH) Delisted | Other (J) | — | $0 | EDGAR |
| 2020-07-20 | FLXN | Grant (A) | +38,750 | $0 | EDGAR |
| 2020-07-01 | KINETA, INC./DE (PTI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-25 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-24 | FLXN | Grant (A) | +1,303 | $14.1K | EDGAR |
| 2020-05-11 | FLXN | Sell (S) | −2,413 | -$26.3K | EDGAR |
| 2020-03-03 | FLXN | Grant (A) | +31,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.